Market Overview
The global rabies vaccine market size was valued at USD 919 million in 2024. The market is projected to grow from USD 960 million in 2025 to USD 1.23 billion by 2032, exhibiting a CAGR of 4.3% during the forecast period.
Rabies vaccine is an active immunizing agent designed to prevent infection caused by the rabies virus, a fatal zoonotic disease. The vaccine stimulates the body's immune system to produce antibodies against the rabies virus, providing both pre-exposure prophylaxis (PrEP) for high-risk groups and post-exposure prophylaxis (PEP) following potential exposure. The primary vaccine types include Vero cell-based vaccines, BHK cell-based vaccines, and chick embryo cell vaccines.
USD 919 million in 2024
2032 USD 1.23 billion by 2032
of 4.3%
By Type
Vero Cell Rabies Vaccine Segment Dominates the Market Due to High Efficacy and Manufacturing Scalability
The market is segmented based on type into:
Vero Cell Rabies Vaccine
Subtypes: Purified, Lyophilized, and others
BHK Cell Rabies Vaccine
Chick Embryo Cell Rabies Vaccine
Subtypes: Live attenuated, Inactivated, and others
By Application
Post-exposure Prophylaxis (PEP) Segment Leads Due to Critical
Need for Preventing Rabies After Potential Exposure
The market is segmented based on application into:
Pre-exposure Prophylaxis (PrEP)
Portable Neuromonitoring Device Market
Post-exposure Prophylaxis (PEP)
Subtypes: WHO Category II, WHO Category III
Veterinary Use
Our Key Players
GSK (Novartis) (UK)
Sanofi-Pasteur (France)
Chengda (China)
Yisheng (China)
Prcmise (China)
https://www.24lifesciences.com
